Clinical Trials

Study Title

A Disease Registry for Patients with Chronic Lymphocytic Leukemia (CLL)

Purpose

To describe current treatment patterns in the real-world setting among CLL patients who are initiating treatment with novel therapies including approved oral kinase inhibitors, BCL2 inhibitors, or other approved anti-CLL therapies/regimens as first- or later-line therapy, & explore the associations with baseline patient characteristics, healthcare resource utilization, & clinical outcomes.

Eligibility

At least 18 years of age

Clinical diagnosis of CLL/SLL

Initiating treatment within +/- 30 days of enrollment

Willing & able to provide written informed consent

Willing & able to complete patient reported outcome questionnaires

Willing & able to provide information on patient survey questionnaires

Willing to provide a blood sample at time of enrollment

Study Process

Contact Principal Investigator for Information